Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Dividends Paid - Preferred Dividends Paid - Preferred Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Lifecore Biomedical, Inc. \De\ (LFCR) Long-Term Debt Issuances (2019 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Long-Term Debt Issuances over the past 8 years, most recently at $31.8 million for Q3 2024.

For Q3 2024, Long-Term Debt Issuances changed N/A year-over-year to $31.8 million; the TTM value through Aug 2024 reached $348.0 million, changed N/A, while the annual FY2025 figure was $128.6 million, 14.05% down from the prior year.
Long-Term Debt Issuances for Q3 2024 was $31.8 million at Lifecore Biomedical, Inc. \De\, down from $149.6 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $150.0 million in Q1 2021 and troughed at $20.0 million in Q2 2021.
A 4-year average of $86.3 million and a median of $89.2 million in 2023 define the central range for Long-Term Debt Issuances.
Biggest five-year swings in Long-Term Debt Issuances: changed 0.0% in 2022 and later skyrocketed 633.16% in 2023.
Year by year, Long-Term Debt Issuances stood at $20.0 million in 2021, then changed by 0.0% to $20.0 million in 2022, then skyrocketed by 633.16% to $146.6 million in 2023, then crashed by 78.3% to $31.8 million in 2024.
Business Quant data shows Long-Term Debt Issuances for LFCR at $31.8 million in Q3 2024, $149.6 million in Q2 2024, and $146.6 million in Q2 2023.